Skip to main content

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

New Drug Application for TP-03 accepted; PDUFA target action date August 25, 2023

Launched disease education, field medical team and payor engagement in anticipation of TP-03 launch

Cash runway anticipated into at least 2026 for the planned commercial launch of TP-03 and continued pipeline development

IRVINE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address patient needs, starting with eye care, through the application of proven science and new technology, today announced financial results for the third quarter ended September 30, 2022, and recent business achievements.

“During 2022, we moved significantly closer to delivering a new potential drug to millions of patients suffering from one of the most common eye diseases, Demodex blepharitis. The NDA acceptance for TP-03 is a critical milestone for Tarsus, patients and the eye care professionals who treat them as we move closer toward potential commercialization. In parallel, we initiated a robust disease education program and launched our field medical team to continue to drive awareness and encourage eye care professionals to diagnose this highly prevalent disease,” said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus. “We also advanced our pipeline with the start of an exploratory Phase 2a study in MGD and are on-track to initiate a Phase 2a study in Lyme disease prevention this quarter. As we look to 2023 and beyond, we are well capitalized with the financial resources we need to continue investing in our priorities to deliver innovative drugs to patients and further drive shareholder value and growth.”

Recent Business Highlights and Corporate Update

  • New Drug Application (NDA) for TP-03 for the treatment of Demodex blepharitis accepted by U.S. Food and Drug Administration (FDA); Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2023
  • Increased Eye Care Professional (ECP) engagement and education to identify and diagnose Demodex blepharitis
    • “Look at the Lids” disease education campaign has generated > 26K unique website visits and nearly 500K digital/media impressions
  • Launched first all optometrist Medical Science Liaison (MSL) team
    • Focused on disease prevalence, diagnosis and impact
    • MSL team deeply versed in medical care / blepharitis and serving all ECPs
  • Launched national payor accounts team
    • Actively engaging with all top commercial and Medicare accounts
    • Each team member has ~20 years of diverse experience including innovative product launches and leadership positions with key payors and other channel partners
  • Presented additional data from Saturn-1 and Saturn-2 at key medical meetings further demonstrating TP-03 as the potential definitive standard of care for Demodex blepharitis
  • Data from the Callisto Phase 1b trial of TP-05, a novel, oral, non-vaccine potential therapeutic for the prevention of Lyme disease, expected by year-end
  • Board of Directors updates
    • Appointed Scott Morrison to the Board and as Audit Committee Chair
    • Michael Ackermann, Ph.D, Co-founder and Chairman planning to transition off the Board by year-end 2022; Wendy Yarno expected to become Lead Independent Director and Bobak Azamian, M.D., Ph.D, Chief Executive Officer, expected to be appointed as Chairman of the Board following Dr. Ackermann’s transition
  • Cash runway anticipated into at least 2026
    • $227 million of cash, cash equivalents and marketable securities as of September 30, 2022
    • $30 million in expected milestones through 2024 from China out-license with $10 million in December 2022 and $5 million in 1Q 2023

2022 Milestones

ProgramMilestoneAnticipated IndicationH1 2022H2 2022
TP-03Topline Pivotal Data (Saturn-2)Demodex blepharitis 
TP-03Initiate Phase 2 (Ersa)Meibomian Gland Disease 
TP-03NDA AcceptanceDemodex blepharitis 
TP-03Initiate Phase 3 (Libra) in China with LianBioDemodex blepharitis 
TP-04Initiate Phase 2 (Galatea)1Rosacea  
TP-05Topline Phase 1b Data (Callisto)2Lyme disease prevention  
TP-05Initiate Phase 2a (Carpo)2Lyme disease prevention  
  1. On-track to initiate in 2023. 2. On-track to complete by year-end 2022.

Third Quarter 2022 Financial Results

  • Third quarter net loss for 2022 was $22.5 million, compared to net loss of $15.7 million for the same period in 2021
  • Third quarter 2022 license fee and collaboration revenue, as part of the strategic partnership with LianBio, was $0, compared to $1.2 million for the same period in 2021
  • Third quarter research and development expenses for 2022 were $10.9 million (inclusive of stock-based compensation of $1.0 million), compared to $10.2 million for the same period in 2021
  • Third quarter general and administrative expenses for 2022 were $12.0 million (inclusive of stock-based compensation of $2.6 million), compared to $6.7 million for the same period in 2021
  • As of September 30, 2022, cash, cash equivalents and marketable securities were $226.6 million

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic which has demonstrated positive results in two pivotal trials for the treatment of Demodex blepharitis, and the New Drug Application has been accepted by the U.S. Food & Drug Administration (FDA) with a PDUFA target action date of August 25, 2023. TP-03 is also being developed for the treatment of Meibomian Gland Disease, and currently being studied in a Phase 2a clinical trial. In addition, Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the potential approval and commercialization of TP-03, the initiation of Phase 2 studies for Lyme disease prevention and the treatment of rosacea, our cash runway expectations, our ability to continue investing in our business, the terms of the license agreement with LianBio, the ability of LianBio to commercialize TP-03 in the Greater China territory, the market size for TP-03 and TP-05, future events and Tarsus’ plans for and the anticipated benefits of its product candidates including TP-03, TP-04 and TP-05, the timing, objectives and results of the clinical trials, anticipated regulatory and development milestones, the board transition matters and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Important factors that could cause actual results to differ materially from those in the forward-looking statements include: Tarsus has incurred significant losses and negative cash flows from operations since inception and anticipates that it will continue to incur significant expenses and losses for the foreseeable future; Tarsus may need to obtain additional funding to complete the development and any commercialization of its product candidates, if approved; Tarsus is heavily dependent on the success of its lead product candidate, TP-03 for the treatment of Demodex blepharitis; the COVID-19 pandemic may affect Tarsus’ ability to initiate and complete preclinical studies and clinical trials, disrupt regulatory activities, disrupt manufacturing and supply chain or have other adverse effects on Tarsus’ business and operations; even if TP-03, TP-04, TP-05, or any other product candidate that Tarsus develops receives marketing approval, Tarsus may not be successful in educating healthcare professionals and the market about the need for treatments specifically for Demodex blepharitis, MGD, rosacea, Lyme disease prevention, and/or other diseases or conditions targeted by Tarsus’ products; the development and commercialization of Tarsus products is dependent on intellectual property it licenses from Elanco Tiergesundheit AG; Tarsus will need to develop and expand the company and Tarsus may encounter difficulties in managing its growth, which could disrupt its operations; the sizes of the market opportunity for Tarsus’ product candidates, particularly TP-03 for the treatment of Demodex blepharitis and MGD, TP-04 for the treatment of Rosacea, as well as TP-05 for the prevention of Lyme disease, have not been established with precision and may be smaller than estimated; the results of Tarsus’ earlier studies and trials may not be predictive of future results; any termination or suspension of, or delays in the commencement or completion of, Tarsus’ planned clinical trials could result in increased costs, delay or limit its ability to generate revenue and adversely affect its commercial prospects; and if Tarsus is unable to obtain and maintain sufficient intellectual property protection for its product candidates, or if the scope of the intellectual property protection is not sufficiently broad, Tarsus’ competitors could develop and commercialize products similar or identical to Tarsus’ products. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2021 filed on March 14, 2022 and the most recent Form 10-Q quarterly filing filed with the SEC, which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223

(In thousands, except share and per share amounts)
 Three Months Ended
September 30,
 Nine Months Ended
September 30,
License fees$  $708  $13,893  $53,067 
Collaboration revenue    532   1,923   3,622 
Total revenues    1,240   15,816   56,689 
Operating expenses:       
Cost of license fees and collaboration revenue    65   555   2,099 
Research and development 10,912   10,209   32,596   33,674 
General and administrative 11,994   6,671   30,316   18,625 
Total operating expenses 22,906   16,945   63,467   54,398 
(Loss) income from operations before other income (expense) and income taxes (22,906)  (15,705)  (47,651)  2,291 
Other income (expense):       
Interest income 1,061   8   1,372   24 
Interest expense (633)     (1,507)   
Other (expense) income, net (7)  5   136   (68)
Unrealized loss on equity investments (13)     (326)   
Change in fair value of equity warrants issued by licensee (18)  (346)  (520)  (1,222)
Total other income (expense), net 390   (333)  (845)  (1,266)
Benefit (provision) for income taxes 5   341   4   (1)
Net (loss) income$(22,511) $(15,697) $(48,492) $1,024 
Other comprehensive (loss) income:       
Unrealized loss on marketable securities and cash equivalents (10)     (10)   
Comprehensive (loss) income$(22,521) $(15,697) $(48,502) $1,024 
Net (loss) income per share, basic$(0.84) $(0.76) $(2.03) $0.05 
Net (loss) income per share, diluted$(0.84) $(0.76) $(2.03) $0.05 
Weighted-average shares outstanding, basic 26,662,374   20,641,285   23,923,512   20,511,973 
Weighted-average shares outstanding, diluted 26,662,374   20,641,285   23,923,512   22,032,487 

(In thousands, except share and par value amounts)
 September 30,
 December 31,
Current assets:   
Cash and cash equivalents$169,489  $171,332 
Marketable securities 57,083   483 
Accounts receivable 17    
Other receivables 3,995   92 
Prepaid expenses 3,494   4,045 
Total current assets 234,078   175,952 
Property and equipment, net 951   755 
Operating lease right-of-use assets 696   1,074 
Long-term investments 157    
Other assets 583   1,126 
Total assets$236,465  $178,907 
Current liabilities:   
Accounts payable and other accrued liabilities$10,181  $8,680 
Accrued payroll and benefits 4,092   2,798 
Total current liabilities 14,273   11,478 
Term loan, net 19,356    
Other long-term liabilities 209   699 
Total liabilities 33,838   12,177 
Commitments and contingencies   
Stockholders’ equity:   
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding     
Common stock, $0.0001 par value; 200,000,000 shares authorized; 26,671,812 shares issued and outstanding at September 30, 2022 (unaudited); 20,726,580 shares issued and 20,698,737 outstanding, which excludes 27,840 shares subject to repurchase at December 31, 2021 5   4 
Additional paid-in capital 297,796   213,398 
Accumulated other comprehensive loss (10)   
Accumulated deficit (95,164)  (46,672)
Total stockholders’ equity 202,627   166,730 
Total liabilities and stockholders’ equity$236,465  $178,907 

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.